See more : Tose Co., Ltd. (4728.T) Income Statement Analysis – Financial Results
Complete financial analysis of CANbridge Pharmaceuticals Inc. (1228.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CANbridge Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hyprop Investments Limited (HYP.JO) Income Statement Analysis – Financial Results
- Servotech Power Systems Limited (SERVOTECH.NS) Income Statement Analysis – Financial Results
- Yijia Group Corp. (YJGJ) Income Statement Analysis – Financial Results
- Scout24 SE (G24.SG) Income Statement Analysis – Financial Results
- Leslie’s, Inc. (LESL) Income Statement Analysis – Financial Results
CANbridge Pharmaceuticals Inc. (1228.HK)
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 102.87M | 78.97M | 31.16M | 12.03M | 1.47M |
| Cost of Revenue | 38.71M | 30.08M | 12.39M | 5.15M | 504.00K |
| Gross Profit | 64.16M | 48.89M | 18.78M | 6.88M | 965.00K |
| Gross Profit Ratio | 62.37% | 61.91% | 60.25% | 57.16% | 65.69% |
| Research & Development | 257.21M | 311.17M | 427.66M | 109.64M | 55.38M |
| General & Administrative | 89.83M | 108.91M | 145.52M | 43.66M | 22.15M |
| Selling & Marketing | 83.67M | 86.78M | 100.75M | 51.01M | 28.88M |
| SG&A | 173.50M | 195.69M | 246.27M | 94.67M | 51.03M |
| Other Expenses | -366.55M | -31.43M | -466.61M | -591.30M | -78.95M |
| Operating Expenses | 64.16M | 498.41M | 673.52M | 237.97M | 137.81M |
| Cost & Expenses | 469.42M | 528.49M | 685.90M | 243.13M | 138.31M |
| Interest Income | 10.98M | 3.89M | 2.61M | 964.00K | 160.00K |
| Interest Expense | 8.95M | 6.86M | 3.08M | 3.79M | 1.35M |
| Depreciation & Amortization | 28.46M | 21.98M | 15.71M | 17.84M | 3.60M |
| EBITDA | -341.43M | -454.63M | -1.06B | -824.41M | -212.73M |
| EBITDA Ratio | -331.90% | -576.24% | -3,537.76% | -6,679.39% | -14,480.19% |
| Operating Income | -366.55M | -477.05M | -1.12B | -821.50M | -216.31M |
| Operating Income Ratio | -356.32% | -604.07% | -3,588.16% | -6,827.65% | -14,724.91% |
| Total Other Income/Expenses | -12.29M | -6.43M | 41.10M | -614.95M | -80.83M |
| Income Before Tax | -378.84M | -483.48M | -1.08B | -846.04M | -217.68M |
| Income Before Tax Ratio | -368.26% | -612.21% | -3,456.26% | -7,031.61% | -14,817.90% |
| Income Tax Expense | 0.00 | 21.75M | 15.47M | 17.63M | 3.42M |
| Net Income | -378.84M | -483.48M | -1.08B | -846.04M | -217.68M |
| Net Income Ratio | -368.26% | -612.21% | -3,456.26% | -7,031.61% | -14,817.90% |
| EPS | -0.89 | -1.14 | -11.43 | -1.99 | -0.51 |
| EPS Diluted | -0.89 | -1.14 | -11.43 | -1.99 | -0.51 |
| Weighted Avg Shares Out | 424.38M | 424.21M | 94.24M | 424.19M | 424.19M |
| Weighted Avg Shares Out (Dil) | 424.38M | 424.21M | 94.24M | 424.19M | 424.19M |
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
Source: https://incomestatements.info
Category: Stock Reports